EP2475360A1 - Use of guaifenesin for inhibiting mucin secretion - Google Patents

Use of guaifenesin for inhibiting mucin secretion

Info

Publication number
EP2475360A1
EP2475360A1 EP10757117A EP10757117A EP2475360A1 EP 2475360 A1 EP2475360 A1 EP 2475360A1 EP 10757117 A EP10757117 A EP 10757117A EP 10757117 A EP10757117 A EP 10757117A EP 2475360 A1 EP2475360 A1 EP 2475360A1
Authority
EP
European Patent Office
Prior art keywords
composition
guaifenesin
administering
effective amount
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP10757117A
Other languages
German (de)
English (en)
French (fr)
Inventor
Helmut Albrecht
K. Chul Kim
Jeanclare Seagrave
Bruce K. Rubin
Gail Solomon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reckitt Benckiser LLC
Original Assignee
Reckitt Benckiser LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/558,517 external-priority patent/US20110065744A1/en
Priority claimed from GBGB1002039.4A external-priority patent/GB201002039D0/en
Application filed by Reckitt Benckiser LLC filed Critical Reckitt Benckiser LLC
Publication of EP2475360A1 publication Critical patent/EP2475360A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the use of a pharmaceutical compound for the inhibition of mucus secretion in an individual.- in particular, the present invention relates to the use of guaifenesin for the inhibition of mucus secretion.
  • Guaifenesin whose chemical name is 3- 2-methoxypheno y)- 1 ⁇ -propanediol, ⁇ is an expectorant.
  • An expectorant is a drug that helps bring up mucus and other material from the lungs, bronchi, and trachea.
  • Guaifenesin is thought to act by thinning the mucus, loosening phlegm and bronchial secretions, and also by lubricating the irritated respiratory -tract By thinning , the mucus, guaifenesin reduces the viscosity of the- mucal.
  • CGPP chronic obstructive pulmonary diseases
  • inflammatory lung diseases asthma, cystic fibrosis and acute or chronic respiratory infectious diseases using compounds of a defined formula having at least two aromatic rings.
  • the applicant has developed a method of inhibiting the secretion of mucus in an. individual which comprises administering an effect ve amount of a composition- -which comprises guaifenesin..
  • a method of inhibiting rmicus secretion in an individual which comprises administering an effective amount. •of a composition which comprises guaifenesin.
  • the composition can contain from approximately 600mg- 1200mg o f guai fenesin.
  • the guaifenesin can be administered in many suitable forms such as a tablet, powder, capsule, liquid or liquigel.
  • the guaifenesin can be administered orally.
  • the mucin can be produced in the upper respiratory tract of an individual.
  • Tire composition can contain one or more additional active agents selected from the group including, but. not limited to, an antitussive such as dextromethorphan hydrobromide, a decongestant such as phenylephrine hydrochloride, pseudoephedrine hydrochloride or ⁇ ephedrine, • an antihistamine such as chlorpheniramine maieate, brompheniramine maieate, phenindamine tartrate, pyrilamine maieate, doxylamine succinate, phenyitoloxamine citrate, diphenhydramine hydrochloride, promethazine, and clemastine fumerate. fexofenadine or a combination thereo
  • an antitussive such as dextromethorphan hydrobromide
  • a decongestant such as phenylephrine hydrochloride, pseudoephedrine hydrochloride or ⁇ ephedrine
  • an antihistamine such as chlorpheniramine
  • the composition can have an immediate release portion and a sustained release poition, such that the inhibition of mucus secretion, is therapeutically achieved for a period of approximately ⁇ 2 hours.
  • the daily dose of guaifenesin can be 24O0mg.
  • a method of treating an individual having a disease or condition characterized by increased mucin secretion with an effective amount of a composition which comprises guaifenesin as described in the first aspect of the present invention is provided.
  • the disease of condition characterized by -increased mucin secretion infectious can be selected from inflammatory conditions of the airways.
  • Fig, 1 illustrates the treatment protocol.
  • Fig. 2 is a graph showing the effect of guaifenesin on MUC5 AC mucin secretion: 30 mm
  • Figs. 3a and 3b are graphs showing the effect of guaifenesin on MUC5AG mucin secretion: 6 hours
  • Figs. 4a and 4b are graphs showing the effect of guaifenesin on MUC5AC mucin secretion: 24 hours
  • Figs. Sa and 5b are graphs showing the effect of guaifenesin on MUC5AC mucin secretion: 48 hours
  • Fig, 6 is a graph showing the effect of guaifenesin on mucociliary clearance.
  • Figs. 7a and 7b are graphs showing metabolic activity.
  • Figs. 8a, 8 b and 8c are graphs showing mucus theology.
  • Figs. 9a and 9b are graphs sho wing the vector sum of viscosity and elasticity against time and dose
  • EpiAirway cultures normal human bronchial epithelial cells grown on Millipore Transwells, 1 or 4.2 cm 2 surface area. The cells were purchased from MatTek, and were cultured, at air-liquid interface for two (mucus synthesis and secretion) or three (mucociliary transport and mucus rheoiogy) weeks prior to use.
  • a stock guaifenesin solution of 2 mg/mL in culture medium was prepared in the morning of each experiment, and kept cold until dilution into warmed medium to the target concentrations of 0,2, 2, 20 or 200 ⁇ g/mL.
  • the medium in the basolateral compartment of each culture was replaced with the GGE-contammg medium, and the cultureswere returned to the 37°C, 5% CO 2 incubator for as the times indicated.
  • the experiments were repeated three times on independent cultures.
  • concentrations used in the in vitro experiments range from 0.2 ⁇ g/mL to 20 mg/mL and thus bracket the clinical doses used in humans.
  • GUAIFENESIN solutions were prepared by dissolving in PBS .(phosphate buffered saline) immediately before treatment of the cells.
  • MUC5AC mucins were quantified by BLISA using 45MI antibody (Lab vis ion, Fremont, CA).
  • Confluent 1 cm * NHBE cells grown on an air/liquid interface were washed from the apical surface with 200 p.L PBS and incubated with fresh, complete growth medium added to the basal chamber. Cultures were incubated 24 hours to collect the apical fluid (pretreatment sample or PT) by adding 100 PBS to the apical, surface of the cultures.
  • PBS was added to dilute the highly viscous, thin mucus layer on the surface. Because of the .small size of the insert, it was not feasible to collect a sufficient amount of mucus for both pharmacology and rheology without the addition of PBS.
  • PT mucus samples
  • cultures were divided into three groups (6 hr, 24 hr and 48 hr), 16 inserts per group, and treated with varying concentrations of guaifenesin (0, 0,2, 2, 20 ⁇ g/mL) for each time group, 4 inserts per each dose. Thus, a total of 48 inserts were used for this study ⁇ 4 inserts/dose x 4 doses/time point x 3 time points).
  • the apical fluid was ' collected at 30 minutes following drug treatment front all the cultures to see whether guaifenesin affects the "secretion" of mucins.
  • the apical, mucus sample was collected in two steps ⁇ first by adding 100 ⁇ . ⁇ PBS to the apical surface ( 1 st wash) and then by adding 100 ⁇ L ⁇ PBS containing 5 mM dilhiothreitol (DTT) (2" a wash). Samples from each wash were assayed for MUC5AC content and the sum of the two values (the 1 st and 2TM wash.) was expressed. -as the '"released MUC5AC" of the culture.
  • Cultures (4.2 cm.') were exposed to basolaieral guaifenesin for 1 or 6 hr. The cultures were removed from the incubator and placed on. the stage of digital imaging microscopy system . Video data were collected for 10 seconds using a. 25x objective. The rate of movement of endogenous cell, debris -was analyzed on the video images using a transparent template overlay on the video images and a stopwatch to measure at least 5 particles on each culture, for a total of between 30 and 45 .measurements per condition.
  • mucus was harvested from the apical surface of the cultures, without dilution.
  • the rheologieal properties of apical mucus secretions (20 p.L) were measured using art ARI000 controlled stress rheometer (TA Instruments:, New Castle, DE) using a parallel plate ⁇ geometry.
  • Rheologie data can also be presented using vectorial notation .as tangent ⁇ which is the ratio of viscosity to elasticity and G*, the vector sum of viscosity and elasticity (mechanical impedance).
  • Fig. 3a the white boxes represent the amount of mucin associated with, the cell, whereas the black boxes represent the amount of mucin released during the given period of treatment. Therefore, the addition of the white box. and the black box represents the total amount of mucin produced during the given period.
  • the total amounts ofMUC5 AC- were compared for statistical differences between control (no guaifenesin) and guaifenesin groups.
  • guaifenesin appeared to increase the mobility of the cellular debris on the surface of cultures treated for 1 hr, but there was little evidence of a dose-response and in fact, only the effect of 2 ⁇ g/ l was statistically significant. However, at the 6 hr time point, there was a strong trend to a dose response and movement of the -surface material for all three concentrations tested was significantly faster than the control as illustrated -in.
  • EpiAirway cultures were treated with the indicated concentrations of guaifenesin ⁇ b.r 1 or 6 his. Mucociliary clearance was assessed, by the rate of mo vement of endogenous debris on. the surfaces. *** indicates significantly different from- the control cultures- at the same time, p ⁇ 0.00.5.
  • G* vector sum of viscosity and elasticity, at 1 rad-'s (Fig. 9a) arid 100 rad/sec (Fig. 9b), segregated by time as well as dose.
  • Viscosity is the loss of energy from a rheoSogie probe or applied, stress and thus the resistance to flow.
  • Elasticity storage modulus.
  • the complex modulus, G* is also known as the mechanical impedance..
  • G* measurement indicates -resistance lo deformation.
  • Viscoelasiieity is a property of non-Newtonian fluids (gels). Dynaraie viseoelasticity measures •the strain response of mucus to an applied stress. Because mucus is subjected- to both low -stress (ciliary beat) and high stress (cough) conditions, we measure the strain developed in response to a dynamic stress.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP10757117A 2009-09-12 2010-09-13 Use of guaifenesin for inhibiting mucin secretion Ceased EP2475360A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/558,517 US20110065744A1 (en) 2009-09-12 2009-09-12 Method Of Inhibiting Mucin Secretion
GBGB1002039.4A GB201002039D0 (en) 2010-02-09 2010-02-09 Method of inhibiting mucin secretion
PCT/GB2010/051525 WO2011030163A1 (en) 2009-09-12 2010-09-13 Use of guaifenesin for inhibiting mucin secretion

Publications (1)

Publication Number Publication Date
EP2475360A1 true EP2475360A1 (en) 2012-07-18

Family

ID=42941393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10757117A Ceased EP2475360A1 (en) 2009-09-12 2010-09-13 Use of guaifenesin for inhibiting mucin secretion

Country Status (12)

Country Link
EP (1) EP2475360A1 (enExample)
JP (1) JP2013504554A (enExample)
KR (1) KR20120068889A (enExample)
CN (1) CN102596189A (enExample)
AU (1) AU2010294008B2 (enExample)
BR (1) BR112012005517A2 (enExample)
CA (1) CA2773611A1 (enExample)
MX (1) MX2012003042A (enExample)
MY (1) MY161187A (enExample)
RU (1) RU2012114323A (enExample)
WO (1) WO2011030163A1 (enExample)
ZA (1) ZA201201822B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1206995A1 (en) * 2012-04-06 2016-01-22 The Uab Research Foundation Methods for increasing cftr activity
KR102211605B1 (ko) * 2018-02-26 2021-02-04 대한민국 개구리 배아를 이용한 기도 뮤신 분비 억제제의 스크리닝 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA963590B (en) * 1995-05-10 1996-11-19 Adcock Ingram Ltd Pharmaceutical composition
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
EP1471872A2 (en) * 2002-02-04 2004-11-03 Pharmacia Corporation Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof
CN1835942A (zh) * 2003-06-19 2006-09-20 金纳莱公司 粘蛋白合成抑制剂
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20080014261A1 (en) * 2006-07-12 2008-01-17 Giordano John A Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20090202633A1 (en) * 2008-01-03 2009-08-13 Siva Ramakrishna Velaga Extended release formulations of guaifenesin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2011030163A1 *

Also Published As

Publication number Publication date
WO2011030163A1 (en) 2011-03-17
ZA201201822B (en) 2013-05-29
CN102596189A (zh) 2012-07-18
AU2010294008B2 (en) 2014-08-14
MY161187A (en) 2017-04-14
BR112012005517A2 (pt) 2016-04-19
CA2773611A1 (en) 2011-03-17
MX2012003042A (es) 2012-05-29
KR20120068889A (ko) 2012-06-27
AU2010294008A1 (en) 2012-04-05
JP2013504554A (ja) 2013-02-07
RU2012114323A (ru) 2013-10-20

Similar Documents

Publication Publication Date Title
Sommerhoff et al. Mast cell chymase. A potent secretagogue for airway gland serous cells.
Wang et al. Cigarette smoke inhibits human bronchial epithelial cell repair processes
Setola et al. 3, 4-methylenedioxymethamphetamine (MDMA,“Ecstasy”) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro
Zhu et al. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells
Wu et al. Clathrin exchange during clathrin-mediated endocytosis
Giuliani et al. Ethanol and acetaldehyde inhibit the formation of early osteoblast progenitors in murine and human bone marrow cultures
Pacher et al. Electrophysiological effects of fluoxetine in mammalian cardiac tissues
Wang et al. Macrophage-derived GPNMB trapped by fibrotic extracellular matrix promotes pulmonary fibrosis
Sagar et al. Obesity impairs cardiolipin-dependent mitophagy and therapeutic intercellular mitochondrial transfer ability of mesenchymal stem cells
Kumar et al. Whole urinary proteins coat calcium oxalate monohydrate crystals to greatly decrease their adhesion to renal cells
Sweeney et al. Silver nanowire interactions with primary human alveolar type-II epithelial cell secretions: contrasting bioreactivity with human alveolar type-I and type-II epithelial cells
Wen et al. Denatonium inhibits growth and induces apoptosis of airway epithelial cells through mitochondrial signaling pathways
Choi et al. Tonsil-derived mesenchymal stem cells incorporated in reactive oxygen species-releasing hydrogel promote bone formation by increasing the translocation of cell surface GRP78
CN103688170A (zh) 使用免疫学技术进行的体外测定方法
EP2475360A1 (en) Use of guaifenesin for inhibiting mucin secretion
Pietras et al. Estrogen-induced membrane alterations and growth associated with proteinase activity in endometrial cells.
Costea et al. Adverse effects of Sudanese toombak vs. Swedish snuff on human oral cells
Laumonier et al. In vitro evaluation of human myoblast function after exposure to cobalt and chromium ions
US20110065744A1 (en) Method Of Inhibiting Mucin Secretion
Heijink et al. Role of aberrant metalloproteinase activity in the pro-inflammatory phenotype of bronchial epithelium in COPD
GB2364385A (en) Alpha 7 nicotinic receptor screening assays
Kuroda et al. Perturbation of lamellar granule secretion by sodium caprate implicates epidermal tight junctions in lamellar granule function
EP4382115A1 (en) Composition for preventing or treating fibrotic diseases, comprising hapln1
Astleford-Hopper et al. Female LSD1 Conditional Knockout Mice Have an Increased Bone Mass
Hao et al. Corneal biomechanical cues mediated by PAI-2: the origin of PM2. 5-induced corneal disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120316

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150922

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20181209